TherapeuticsMD (TXMD) Non-Current Debt (2011 - 2021)

TherapeuticsMD has reported Non-Current Debt for 6 years, with the latest figure at $171.7 million in Q3 2021.

• For the quarter ending Q3 2021, Non-Current Debt fell 27.55% year-over-year to $171.7 million; the trailing twelve-month figure through Sep 2021 stood at $171.7 million (down 27.55% YoY), and the FY2020 full-year result was $237.7 million, up 22.13% from the prior year.
• Non-Current Debt for Q3 2021 stood at $171.7 million, down from $175.3 million in the prior quarter.
• The five-year high for Non-Current Debt was $243.8 million in Q2 2020, with the low at $73.1 million in Q2 2018.
• Historically, Non-Current Debt has averaged $168.9 million across 4 years, with a median of $186.5 million in 2019.
• Annual changes were most pronounced in 2020 — Non-Current Debt jumped 231.19% — and 2021, when it declined 28.11%.
• TherapeuticsMD's Non-Current Debt stood at $73.4 million in 2018, then soared by 165.24% to $194.6 million in 2019, then grew by 22.13% to $237.7 million in 2020, then retreated by 27.75% to $171.7 million in 2021.
• The last three Non-Current Debt figures came in at $171.7 million (Q3 2021), $175.3 million (Q2 2021), and $179.0 million (Q1 2021), per Business Quant data.